Hypertension is the leading cause of mortality throughout Asia. Home blood pressure monitoring has the potential to improve hypertension control and is a useful adjunct to conventional office blood pressure measurements due to its diagnostic accuracy and prognostic value in predicting cardiovascular outcomes. At present, there are no region-specific guidelines addressing the use of home blood pressure monitoring in Asia. Therefore, an expert panel was convened to address the use of home blood pressure monitoring and develop key recommendations to help guide clinical practice throughout the Asia region. The resulting recommendations support the use of home blood pressure monitoring with a validated device as an accurate adjunct for diagnosing hypertension and predicting cardiovascular outcome. Diagnosis and treatment of hypertension should still be guided by conventional office/clinic blood pressure measurements. The expert panel encourages the incorporation of home blood pressure monitoring into local clinical guidelines and offers practical recommendations to ensure continuity of care where a validated home blood pressure device is not available.
Bibliographical noteFunding Information:
Funding The development of this article was made possible through a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant Number: HI13C0715); and a grant from the Foundation for Development of the Community (Tochigi, Japan). Editorial and writing support was provided by Howard Christian and Chris Facey of MIMS (Hong Kong) Limited and was funded by Pfizer. The meeting during which these recommendations were formulated and discussed was made possible by an unrestricted educational grant from Pfizer. However, the recommendations were developed by the HOPE Asia Network independently of Pfizer.
Conflict of interest C-HC has received honoraria for serving as a speaker or member of a speaker bureau for AstraZeneca, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Merck & Co, Novartis, Pfizer, Sanofi, Servier, and Takeda. Y-CC has received honoraria for serving as a speaker, advisor, or chair for Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Medtronic, MSD, Novartis, Pfizer, Reckitt Benckiser, Sanofi, Servier, and Takeda; and sponsorship to scientific conferences from Medtronic, Pfizer, Reckitt Benckiser, Servier, and Takeda. She is also the current President of the Malaysian Society of Hypertension, with an interest in promoting the use of home BP measurements. Omron Healthcare and other manufacturers of digital blood pressure devices have supported the society’s annual scientific conference and several BP screening public health activities. KK has received research grants from A&D Co., Bayer Yakuhin, Boehringer Ingelheim, Daiichi Sankyo, EA Pharma, Fukuda Denshi, Medtronic, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Omron Healthcare, Otsuka, Pfizer, Takeda, and Teijin Pharma; and honoraria from Daiichi San-kyo, Omron Healthcare, and Takeda. SP has received honoraria from Astellas and Pfizer; and consultation fees from Takeda. SS has received honoraria from Bayer, Novartis, Pfizer, Sanofi Aventis, and Servier; and travel, accommodation, and conference registration support from Atco Pharmaceutical, Bayer, Highnoon Laboratories, Novartis, Pfizer, Sanofi Aventis, and Servier. GPS has received a research grant related to hypertension monitoring and treatment from Pfizer. YZ has received research grants from Bayer, Novartis, and Shuanghe; and lecture fees from Bayer, Daiichi Sankyo, MSD, Novartis, Pfizer, Sanofi, Servier, Shuanghe, and Takeda. The other authors declare that they have no conflict of interest.
All Science Journal Classification (ASJC) codes
- Internal Medicine